Advancing Access to Care Through Innovation
Sedia™ HIV-1 LAg-Avidity EIA for Dried Blood Spots
Sedia™ HIV-1 LAg-Avidity EIA for use with Dried Blood Spot Specimens
The Sedia™ HIV-1 Limiting Antigen (LAg)-Avidity EIA for Dried Blood Spots is suitable for use with dried blood spot specimens. The assay is similar to the original Sedia™ HIV-1 LAg-Avidity EIA used for liquid plasma and serum specimens, except that a different Sample Diluent is used and the controls provided are in the form of dried blood spot (DBS) cards in place of liquid controls. The assay is not suitable for dried serum spot or dried plasma spot specimens.
- Controls provided in card form, from which user prepares punch. Eliminates variability due to differences between hole punches that may be encountered between use of pre-punched controls and specimens punched by user (see below).
- Wash Buffer is compatible with Sedia™ HIV-1 LAg-Avidity EIA Wash Buffer and Sedia™ BED HIV-1 Incidence Assay Wash. Run multiple assays without changing Wash Buffer.
The dried blood spot controls and Calibrator each contain the same serum controls and Calibrator contained in the Sedia™ HIV-1 LAg-Avidity EIA but in dried blood spot form. The control and Calibrator cards are prepared by drying control and Calibrator reagents onto Whatman #903 paper. The user punches out control and Calibrator punches using the same size paper puncher as used for punching out the specimens. Control and Calibrators are not provided as pre-punched spots, since some customers may use U.S. style paper punchers (0.25 in. diameter, 6.4 mm diameter) and others may use metric-style punchers (6 mm. diameter, 0.236 in. diameter). This represents more than 12% difference between punch surface area or collected blood volume. Because of the sensitivity of the HIV-1 LAg-Avidity EIA, users should be sure they are using the same hole punch to punch out disks from both the specimens to be tested and the controls and Calibrator card. According to NCCLS, "the blood spot punch is a volumetric measurement for an analytical method, a high degree of uniformity is essential" and recommends that "the paper puncher’s performance should be calibrated by punching filter paper dots and weighing them."¹
The Sedia™ HIV-1 Limiting Antigen-Avidity EIA for Dried Blood Spots is an in vitro quantitative limiting antigen (LAg) avidity enzyme immunoassay for distinguishing recent HIV-1 infections from those which are long-term. Persons with recently acquired HIV-1 infections typically exhibit HIV-1 specific IgG populations with higher proportions of lower avidity IgG than those with long-term infections which typically exhibit higher proportions of higher avidity IgG.The Sedia™ HIV-1 LAg-Avidity EIA for Dried Blood Spots uses U.S. Centers for Disease Control and Prevention (CDC) developed technology and is designed for surveillance purposes such as estimating HIV-1 incidence in a population, monitoring and evaluating HIV intervention programs, and identifying high-incidence populations for prevention research, vaccine trials, and ensuring that resources are most effectively utilized.
|
Cat. No. 1002 |
Sedia™ HIV-1 LAg-Avidity EIA, 192 Tests (for liquid serum and plasma specimens)(click here for more information) |
|
Cat. No. 1003 |
Sedia™ HIV-1 LAg-Avidity EIA for Dried Blood Spots, 192 Tests |
Each Sedia™ HIV-1 LAg-Avidity EIA for Dried Blood Spots lot is tested by both Sedia's Quality Control Department and by the U.S. Centers for Disease Control prior to market release.
Certification of U.S. CDC testing and approval is provided with each assay kit.
Use of the Sedia™ HIV-1 LAg-Avidity EIA for DBS in the U.S.